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Abstract: BACKGROUND CONTEXT: Transplantation of bone marrow cells into spinal cord lesions 
promotes functional recovery in animal models and recent clinical trials suggest possible recovery also 
in humans. The mechanisms responsible for these improvements are still unclear.  
PURPOSE: To characterise spinal cord motor neurite interactions with human bone marrow stromal 
cells (MSC) in an in vitro model of spinal cord injury (SCI).  
STUDY DESIGN/SETTING: Previously we have reported that human MSC promote the growth of 
extending sensory neurites from dorsal root ganglia (DRG), in the presence of some of the molecules 
present in the glial scar which are attributed with inhibiting axonal regeneration following SCI. We 
have adapted and optimized this system replacing the DRG with a spinal cord culture to produce a 
central nervous system (CNS) model which is more relevant to the SCI situation.  
METHODS: We have developed and characterised a novel spinal cord culture system. Human MSC were 
co-cultured with spinal motor neurites in substrate choice assays containing glial scar associated 
inhibitors of nerve growth. In separate experiments MSC conditioned media was analysed and added 
to spinal motor neurites in substrate choice assays. This study was funded by the corresponding 
author's institution; there are no conflicts of interest. 
RESULTS: As has been reported previously with DRG, substrate-bound neurocan and Nogo-A repelled 
spinal neuronal adhesion and neurite outgrowth, but these inhibitory effects were abrogated in MSC/ 
spinal cord co-cultures. However, unlike DRG, spinal neuronal bodies and neurites showed no 
inhibition to substrates of myelin associated glycoprotein. In addition, the MSC secretome contained 
numerous neurotrophic factors which stimulated spinal neurite outgrowth, but these were not 
sufficient stimuli to promote spinal neurite extension over inhibitory concentrations of neurocan or 
Nogo-A.  
CONCLUSIONS: These findings provide novel insight into how MSC transplantation may promote 
regeneration and functional recovery in animal models of SCI and in the clinic, especially in the chronic 
situation where glial scars (and associated neural inhibitors) are well established. In addition, we have 
confirmed that this CNS model predominantly comprises of motor neurons via immunocytochemical 
characterisation. We hope that this model may be used in future research to test various other 
potential interventions for spinal injury or disease states. 
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Dear Editor, 
Thank you for your consideration of the above manuscript for consideration of publication in The 
Spine Journal; the following points are made in response to the comments of Reviewer 3:  
We are grateful to the reviewer for considering our submission further. It seems that the main (only) 
issue for the Reviewer is because of the evident quality of the images that have been supplied in the 
Figures for the paper. In particular, the Reviewer is concerned that the spinal neurons being 
examined may not have an appropriate morphology for spinal motor neurons. In fact, we have used 
SC1 immunolocalisation as a marker for motor neurons because this marker has previously 
demonstrated specificity for motor neurons (as documented in the script) and because morphology 
alone is a poor indicator of function. Furthermore, we have used isolation and culture techniques 
that also have been demonstrated to successfully obtain motor neurons from chick spinal cords.  
Hence, whilst we understand the point that has been made, we would refute the Reviewer's concern 
in the first instance. However, if you think this remains an issue of note, then we would be happy to 
consider addressing the terminology applied to the neurons being examined, i.e., to describe them 
as spinal neurons rather than motor neurons, and include in the text that we have demonstrated 
that they are SC1 immunopositive. We hope that you agree with us that this edit is not necessary. 
To solve the issue, it may be possible to improve the quality of the final figures by sending individual 
powerpoint files, or the tiff or jpeg files that constitute each Figure proper. Indeed, the Figures have 
now been submitted as Power point files to optimise resolution, which we have uploaded to the 
website, but because of potential difficulties of submitting in this manner, we have also sent the 
individual files (powerpoint files for each Figure proper) to The Spine J., along with the individual 
constituent tiffs for each Figure.  We hope that the new files will have solved the problem of figure 
resolution. 
Thank you for reconsidering this submission to The Spine Journal, which would be an excellent 
journal in which to disseminate this work.  However, we would like to reiterate that it is not possible 
to repeat these studies. 
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Title: Spinal motor neurite outgrowth over glial scar inhibitors is enhanced 1 
by co-culture with bone marrow stromal cells 2 
Abstract 3 
BACKGROUND CONTEXT: Transplantation of bone marrow cells into spinal 4 
cord lesions promotes functional recovery in animal models and recent clinical 5 
trials suggest possible recovery also in humans. The mechanisms responsible for 6 
these improvements are still unclear.  7 
PURPOSE: To characterise spinal cord motor neurite interactions with human 8 
bone marrow stromal cells (MSC) in an in vitro model of spinal cord injury (SCI).  9 
STUDY DESIGN/SETTING: Previously we have reported that human MSC 10 
promote the growth of extending sensory neurites from dorsal root ganglia 11 
(DRG), in the presence of some of the molecules present in the glial scar which 12 
are attributed with inhibiting axonal regeneration following SCI. We have adapted 13 
and optimized this system replacing the DRG with a spinal cord culture to 14 
produce a central nervous system (CNS) model which is more relevant to the SCI 15 
situation.  16 
METHODS: We have developed and characterised a novel spinal cord culture 17 
system. Human MSC were co-cultured with spinal motor neurites in substrate 18 
choice assays containing glial scar associated inhibitors of nerve growth. In 19 
separate experiments MSC conditioned media was analysed and added to spinal 20 
motor neurites in substrate choice assays. This study was funded by the 21 
corresponding author's institution; there are no conflicts of interest. 22 
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RESULTS: As has been reported previously with DRG, substrate-bound 1 
neurocan and Nogo-A repelled spinal neuronal adhesion and neurite outgrowth, 2 
but these inhibitory effects were abrogated in MSC/ spinal cord co-cultures. 3 
However, unlike DRG, spinal neuronal bodies and neurites showed no inhibition 4 
to substrates of myelin associated glycoprotein. In addition, the MSC secretome 5 
contained numerous neurotrophic factors which stimulated spinal neurite 6 
outgrowth, but these were not sufficient stimuli to promote spinal neurite 7 
extension over inhibitory concentrations of neurocan or Nogo-A.  8 
CONCLUSIONS: These findings provide novel insight into how MSC 9 
transplantation may promote regeneration and functional recovery in animal 10 
models of SCI and in the clinic, especially in the chronic situation where glial 11 
scars (and associated neural inhibitors) are well established. In addition, we have 12 
confirmed that this CNS model predominantly comprises of motor neurons via 13 
immunocytochemical characterisation. We hope that this model may be used in 14 
future research to test various other potential interventions for spinal injury or 15 
disease states. 16 
17 
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Introduction 1 
Injury to the central nervous system (CNS) usually initiates a poor intrinsic 2 
regenerative response for a number of reasons. Immune reactions, which in 3 
other tissues may help to recruit reparative cells, often have a devastating effect 4 
on CNS tissue function. Inflammation and ensuing secondary cascades can 5 
cause extensive neuronal and glial cell death, as well as glial cell activation and 6 
hypertrophy [1].  In an effort to restore the blood brain barrier, astrocytes at the 7 
site of injury become reactive and synthesise a proteoglycan rich matrix [2]. 8 
Myelin debris associated molecules, including Nogo-A and myelin associated 9 
glycoprotein (MAG), are also released from damaged neural tissues [3]. These 10 
events combine to produce a hostile environment for nerve re-growth [2-6].  11 
 There has been extensive interest world-wide in the development of cell 12 
transplantation strategies for the treatment of CNS damage, in particular spinal 13 
cord injury (SCI). Many diverse potential cell therapies have been tested, each 14 
targeting different distinct stages of SCI and mechanisms of spinal cord repair [7-15 
10]. Allogeneic embryonic stem cells (ES cells) and umbilical cord-derived cells, 16 
as well as possible autologous cell sources, including adult neural stem cells, 17 
Schwann cells and olfactory ensheathing cells have been shown to promote 18 
axonal regeneration and restore function in animal models of SCI [11-17]. These 19 
types of cell are thought to act in a number of ways depending on the cell type 20 
transplanted, including replacing dead or damaged neurons and glia, re-21 
establishing neural networks, remyelinating demyelinated axons and reducing the 22 
hostile nature of the SCI lesion.  23 
 4 
 
 Autologous cell therapies derived from bone marrow have also been 1 
shown to enhance functional recovery in animal models of SCI and possibly in 2 
the clinic [10], but the repair mechanisms responsible are still largely unclear. 3 
Some controversial evidence exists which suggests that bone marrow cells, 4 
including marrow stromal cell (MSC) and hematopoietic stem cell fractions, may 5 
transdifferentiate to replace lost neurons and glia, in a manner similar to that 6 
proposed for ES cells and neural stem cells [18-22]. However, the consensus of 7 
opinion seems to be that for MSC transplantation at least, the most likely mode of 8 
activity is an induction of a diverse myriad of paracrine anti-inflammatory 9 
pathways and directly restorative cell-matrix and cell-cell interactions [23-29]. 10 
 Previously we have used growth substrate choice assays to examine how 11 
human MSC influence neurite outgrowths from explants of chick dorsal root 12 
ganglia (DRG). We have demonstrated that MSC help neurites to overcome the 13 
effects of some of the major nerve inhibitory molecules found in SCI lesions, 14 
including neural proteoglycans, Nogo-A and MAG [30]. This established model of 15 
sensory nerve growth provided an excellent platform to examine in real-time 16 
possible cell-matrix and cell-cell interactions that may occur in the SCI milieu. In 17 
the current study, we have adapted and refined our system by replacing DRG 18 
explants with spinal cord cultures to provide a more relevant model of CNS nerve 19 
growth. We envisage that the establishment of a novel spinal nerve growth 20 
substrate assay, which comprises characterized motor neurons and relevant 21 
neural matrix molecules, will provide an invaluable research tool for testing SCI 22 
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therapeutics, which will have further applications in the broader fields of CNS 1 
tissue engineering and repair. 2 
3 
 6 
 
Materials and methods 1 
Ethics Statement 2 
All research involving human participants was completed with written informed 3 
consent and Local Research Ethics Committee (LREC) approval: Shropshire & 4 
Staffordshire Strategic Health Authority, Reference Number: 04/02/RJH. Ethical 5 
approval and a Home Office project license for the study were not required under 6 
the United Kingdom Animal (Scientific Procedures) Act of 1986 because chicks 7 
were killed by decapitation (which is an appropriate method under Schedule 1 of 8 
the Act).  9 
Human bone marrow stromal cell (MSC) culture  10 
Bone marrow aspirates or bone chips were harvested from the iliac crest of 11 
individuals undergoing spinal fusion in the treatment for lumbar degenerative 12 
disorders (n=5; ages 29-53). Bone marrow aspirates and bone chips were kindly 13 
collected by spinal surgeons from the Centre for Spinal Disorders and sent to the 14 
Spinal Studies research laboratories for processing (both based at the RJAH 15 
Orthopaedic Hospital, Oswestry, UK). 16 
 Bone chips were perfused with Dulbecco’s Modified Eagle’s Medium 17 
(DMEM/F12), supplemented with 10% fetal bovine serum (FBS) and 1% penicillin 18 
and streptomycin (P/S) (Invitrogen Life Technologies, Paisley, UK). Mononuclear 19 
cells isolated by density gradient centrifugation at 900g for 20 minutes over 20 
Lymphoprep™ (Fresenius Kabi Norge, AS) were plated out in DMEM/ 20% FBS 21 
+ P/S medium (Invitrogen Life Technologies) at a seeding density of 20 x 106 22 
cells per flask. After 24 hours, non-adherent cells were removed and the 23 
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adherent cell populations were cultured in monolayer and were maintained in a 1 
humidified atmosphere of 5% CO2 at 37
0C through to passage II-III in DMEM/ 2 
10% FBS + P/S medium. MSC cultures used in this study were characterised 3 
according to the MSC CD immunoprofile criteria published by the International 4 
Society for Cellular Therapy [31]. 5 
Embryonic chick neuronal cultures  6 
Spinal cords were dissected from E4.5 hybrid brown chicks as described 7 
previously [32] and cut into 10-20 pieces per cord, such that all were of 8 
approximately equal size. These were then digested in 20l of trypsin (2.5% w/v; 9 
final concentration 0.05%) in PBS (Invitrogen Life Technologies) for 15 minutes 10 
at 370C whilst agitating frequently. The trypsin supernatant was removed and 11 
replaced by 900l of neuronal culture medium (NCM; L-15 culture medium 12 
supplemented with 1% (v/v) insulin, transferrin and selenium, 1% (v/v) P/S (L-15/ 13 
ITS-X/ P/S medium, Invitrogen Life Technologies), 1% (v/v) horse serum and 14 
1.5mg/ml glucose) (Sigma-Aldrich, Poole, UK) and 100l of 4% (w/v) bovine 15 
serum albumin (BSA; Sigma-Aldrich). The spinal cord tissue was homogenized 16 
using a pipette and spinal cord motor neurons were isolated by density gradient 17 
centrifugation at 500g for 15 minutes over a warmed 1.5ml cushion of 6.8% (v/v) 18 
Nycodenz® (Serva, Heidleberg, Germany). Dissociated cells were seeded into 19 
24-well tissue culture plates (Co-star, Corning Inc, NY) pre-coated with nerve- 20 
permissive and nerve-inhibitory molecules (see below) in NCM supplemented 21 
with 0.4% (v/v) N2-supplement and 10ng/ml basic fibroblast growth factor (bFGF) 22 
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(Invitrogen Life Technologies) at a seeding density of 3 x 105 cells per well and 1 
were maintained in a humidified atmosphere of 5% CO2 at 37
0C for 72 hours. 2 
Optimisation of chick neuronal culture growth substrata  3 
Briefly, some wells were pre-coated with a thin layer of protein-binding 4 
nitrocellulose (BA85, Schleicher & Schuell, Dassel, Germany). Pre-coated and 5 
uncoated plates were then further incubated with either PBS or 25μg/ml laminin 6 
(derived from Engelbreth-Holm-Swarm mouse tumour, BD Biosciences, Oxford, 7 
UK) in PBS. After coating, all wells were washed repeatedly with PBS prior to 8 
seeding with neuronal cultures.  Control DRG plates for SC1 immunostaining 9 
were established using embryonic chick day 10 DRG as described previously 10 
[30]. 11 
MSC/ neuronal co-cultures  12 
MSC were labelled with Cell TrackerTM Red Fluorescent Probe (Cambrex 13 
Bioscience, Wokingham, UK) following the manufacturer’s protocol.  Labelled 14 
cells were seeded (at a density of 5 x 103 cells/ cm2) in DMEM/ 10% FBS + P/S 15 
into plates coated with nerve-permissive and nerve-inhibitory substrata (see 16 
below). After 24 hours, any non-adherent cells were removed and wells washed 17 
repeatedly before adding N2 and bFGF-supplemented NCM. Neuronal cultures 18 
were then immediately seeded into each well and the MSC/ neuronal co-cultures 19 
maintained in a humidified atmosphere of 5% CO2 at 37
0C for 72 hours. Control 20 
plates of neuronal cultures seeded alone, i.e., without pre-seeded MSC, were 21 
established at the same time in N2 and bFGF-supplemented NCM. 22 
Mixed substrate preparation  23 
 9 
 
Neurocan, isolated from embryonic chick brains and purified with a monoclonal 1 
antibody (Millipore, Billerica, MA), was used to coat tissue culture plates in 2 
restricted localities, as described previously [30, 33,34]. Briefly, wells were pre-3 
coated with a thin layer of protein-binding nitrocellulose (see above), which was 4 
then blotted with 350μm wide strips of filter paper (Whatman No.1, GE 5 
Healthcare, Maidstone, Kent, UK) that had been soaked in neurocan at 6 
concentrations ranging from 1μg-50μg/ml (in PBS). After the filter strips had dried 7 
and been removed, the plates were then washed with PBS. The restricted 8 
localisation of the neurocan on the culture plates was visualized by inclusion of a 9 
marker dye (5% v/v rhodamine B, Sigma-Aldrich) in the neurocan solution. The 10 
same technique was used to prepare culture plates with substrates of 10-11 
400μg/ml recombinant Nogo-A on nitrocellulose or 10-400μg/ml recombinant 12 
MAG on nitrocellulose (both R&D Systems, Abbingdon, UK). After coating, all 13 
wells were washed repeatedly with PBS prior to seeding with neuronal cultures 14 
and/ or MSC. 15 
SC1 and neurofilament (NF) 200kD immunostaining  16 
SC1 is a cell surface adhesion molecule expressed on motor neuron cell bodies 17 
and axons [35], which can be used to purify motor neurons from spinal cord 18 
tissues [36]. Neuronal cell cultures were immunolabelled with SC1 for motor 19 
neuron characterisation, whereas NF immunolabelling was used for neurite 20 
quantitation because the NF immunofluorescence was much stronger and hence 21 
better for the counting of fine neurite extensions. 22 
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 Neuronal cell cultures were fixed by gently adding an equal volume of 4% 1 
(w/v) buffered paraformaldehyde (BDH Biosciences) to the culture medium in 2 
each well for 10 minutes. Wells were washed with PBS twice for 10 minutes. 3 
Cells were then incubated for 1 hour with a blocking buffer of 10% goat serum 4 
(Vector Laboratories, Burlingame, CA) in PBS at room temperature. Mouse 5 
monoclonal anti-SC1 (neat) (kindly donated by Prof Hideaki Tanaka, Kumamoto 6 
University, Japan) or anti-NF (1:200) (clone NE14, Sigma-Aldrich) were used as 7 
the primary antibodies, and goat anti-mouse Alexa Fluor 488 (1:100) (Invitrogen 8 
Life Technologies) was used as a secondary antibody. Cells were incubated with 9 
the primary antibody for 1 hour and the secondary antibody for 40 minutes at 10 
room temperature to stain neuronal bodies and their neurites fluorescent green. 11 
Fibronectin and laminin immunostaining 12 
 MSC cultures were fixed by gently adding an equal volume of 4% (w/v) buffered 13 
paraformaldehyde to the culture medium in each well for 10 minutes. Wells were 14 
washed with PBS twice for 10 minutes. Cells were then incubated for 20 minutes 15 
with a blocking buffer of 15% horse serum (Vector Laboratories) in PBS at room 16 
temperature. Rabbit polyclonal anti-fibronectin (250g/ml) or anti-laminin 17 
(25g/ml) (both, Sigma-Aldrich) were used as the primary antibodies, and 18 
biotinylated goat anti-rabbit (50g/ml, Vector Labs) was used as a secondary 19 
antibody followed by a fluorescein-streptavidin complex (20g/ml, Vector Labs). 20 
Parallel wells were incubated in the same blocking buffer as negative controls for 21 
polyclonal antibodies.  Cells were incubated with the primary antibody or blocking 22 
 11 
 
buffer overnight, the secondary antibody for 40 minutes and the fluorescein-1 
streptavidin complex for 20 minutes at room temperature. 2 
MSC-CM neuronal culture assays 3 
MSC-CM (n=6) were generated as described previously [30] and stored at -20oC 4 
prior to use. In brief, MSC cultures at 70% confluence were incubated in serum 5 
free DMEM supplemented with antibiotics at 37oC, 5% (v/v) CO2 for 48 hours. 6 
The MSC-CM generated from these cultures was passed through a 0.2m filter 7 
(Becton Dickinson Biosciences) to remove any cell debris and stored at -200C 8 
prior to use, which was within one week of collection.  Neuronal cell cultures were 9 
seeded in MSC-CM in culture plates that had either been uniformly coated in 10 
nitrocellulose or coated with nitrocellulose and  strips of neurocan (50g/ml) or 11 
Nogo-A (400g/ml), as described above. Control neuronal cultures were 12 
maintained in non-conditioned media under the same conditions. Neurite 13 
outgrowth was measured after 72 hours in culture. 14 
MSC-CM neurotrophic protein arrays 15 
MSC-CM were screened for a panel of 23 neurotrophic proteins using custom 16 
designed antibody arrays (RayBiotech Inc, Norcross, GA) according to the 17 
manufacturer's instructions. In brief, array membranes with protein antibodies 18 
spotted in duplicate were incubated with blocking buffer for 30 minutes at room 19 
temperature. MSC-CM were thawed and incubated with the membranes 20 
overnight at 4°C. Membranes were washed and then incubated with a Biotin-21 
conjugated antibody for 1 hour. Wash steps were repeated as before and 22 
membranes incubated with HRP-conjugated streptavidin for 2 hours. Following 23 
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another series of wash steps, membranes were incubated with a 1 
chemiluminescent detection reagent provided in the kit for 2 minutes. Positive 2 
signals were visualised with a chemiluminescence imaging system (ChemiDoc™ 3 
EQ, Bio-Rad Laboratories Srl, Italy). Array data was semi-quantified by 4 
measuring the sum of the intensities of the pixels within each spot boundary x 5 
pixel area, with image analysis software (Quantity One® version 4.6.3, Bio-Rad, 6 
Italy). A signal from a clear part of the array was subtracted from all data to 7 
account for background signal. A mean was taken from the two duplicate spots 8 
for each factor. Levels of neurotrophic factors were normalised to positive 9 
controls (provided in the kit) and to the number of MSC that had generated a 10 
standard volume of conditioned media. 11 
Microscopy, image capture and analysis 12 
Cultures were viewed using phase contrast and fluorescence microscopy (Nikon 13 
Eclipse TS100, Nikon, Kingston-upon-Thames, UK). Digitized images were 14 
captured with a black and white Hamamatsu digital camera (C4742-95) and 15 
examined using IPLab software (Version 3.6, Nikon). For determination of the 16 
optimal substrate for growth of embryonic chick spinal neuronal cultures, cell 17 
aggregates and neuronal adhesion, and neurite outgrowth were counted using 18 
phase contrast and fluorescence images. A cell aggregate was determined as a 19 
cluster of more than one adhered cell visible under phase microscopy. NF 20 
immunolabelling, visible under fluorescence microscopy was used to stain 21 
neurites and to determine those cell aggregates that were of a neuronal 22 
phenotype. Hence, those cell aggregates that were immunopositive for NF and 23 
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possessed neurites (that is, if a neurite ≥25m in length were in contact with a 1 
neuronal cell aggregate) were then described as ‘neuronal bodies’.  For substrate 2 
choice assays, the number of neuronal bodies with neurites that had adhered 3 
onto substrates of plastic, nitrocellulose, laminin, neurocan, Nogo-A or MAG were 4 
quantified using fluorescent images. For all analysis, adhered neuronal bodies 5 
with neurites were counted after 72 hours in culture. The number of red 6 
fluorescent MSC that were present on the nitrocellulose, neurocan, Nogo-A or 7 
MAG substrates in each digitized image was also scored. For substrate choice 8 
assay quantitation, results from at least 5 separate cultures and 5 separate 9 
images per culture were pooled and combined and examined using IPLab 10 
software (Version 3.6, Nikon). 11 
 MSC-CM neurite outgrowth assays were viewed and quantified using 12 
phase contrast microscopy and digitized images captured and examined using 13 
the Cell IQ® Imagen system and Analyser software (Chip-Man Technologies, 14 
Tampere, Finland). In brief, phase contrast images of cultures (n=12 controls and 15 
n=24 MSC-CM) were captured using a fully automated system every 2-3h over a 16 
period of 72 hours. From these images, the Cell-IQ® Analyser software 17 
automated search tool ‘neurite finder’ generated temporal neurite length data for 18 
each culture condition. 19 
Statistical analysis  20 
The Mann-Whitney U test was used to assess significant differences: (i) between 21 
the frequency of neuronal bodies adhered with extending neurites onto uniform 22 
substrates of plastic, nitrocellulose and laminin, (ii) between the frequency of 23 
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neuronal bodies adhered with extending neurites onto each of the adjacent 1 
substrates in substrate choice assays of nitrocellulose versus neurocan, Nogo-A 2 
or MAG in neuronal and MSC co-cultures, compared to control neuronal cultures 3 
alone, (iii) between the frequency of MSC adhered onto each of the adjacent 4 
substrates in substrate choice assays of nitrocellulose versus neurocan, Nogo-A 5 
or MAG. The relationship between the relative amounts of each neurotrophic 6 
protein and the total neurite outgrowth in each MSC-CM was determined using 7 
the Spearman ranked correlation coefficient rs. 8 
Results 9 
Nitrocellulose substrates promote optimal growth of embryonic chick spinal 10 
neuronal cultures. 11 
Embryonic chick spinal cells formed aggregates which adhered to both plastic 12 
and nitrocellulose substrates with or without laminin coating to varying degrees 13 
(Fig 1A). A number of fibroblastic cells adhered to substrates of plastic alone; a 14 
small proportion of these cells extended neurites but these were difficult to 15 
distinguish from neighbouring aggregates in close proximately. Cells seeded onto 16 
substrates of plastic coated with laminin or nitrocellulose formed discrete cell 17 
aggregates and the majority of these aggregates possessed neurites. The 18 
frequency of neurites was increased on substrates of plastic coated with 19 
nitrocellulose compared to plastic (with or without laminin) (Fig 1B). For 20 
substrates of nitrocellulose coated plastic with laminin, fibroblastic cells were so 21 
confluent they could not be reliably separated for quantitation. 22 
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 Embryonic chick spinal cell aggregates and neurites were then fixed and 1 
immunostained for neurofilament (NF) (Fig 1C). A large proportion of those cell 2 
aggregates which had adhered to plastic alone were lost following fixation and 3 
immunostaining. The discrete cell aggregates which had adhered to the laminin 4 
or nitrocellulose coated plastic were identified as NF immunoreactive. Those NF 5 
immunoreactive cell aggregates that had extended NF immunoreactive neurites 6 
were identified as neuronal bodies. The frequency of neuronal bodies was 7 
increased on substrates of nitrocellulose coated plastic compared to plastic (with 8 
or without laminin) (Fig 1D). For substrates of nitrocellulose coated plastic with 9 
laminin, there was no clear aggregation of NF immunoreactive cells to form 10 
discrete neuronal bodies, with a confluence of cells growing across the substrate 11 
instead; hence the distribution of discrete NF immunoreactive neuronal bodies 12 
with neurites could not be measured. 13 
Embryonic chick spinal neuronal cultures are immunopositive for the motor 14 
neuron marker SC1 15 
Embryonic chick dorsal root ganglion (DRG) cultures were negative for SC1 16 
immunocytochemical staining as were isotype matched control wells (Figs 2A 17 
and 2B). In contrast, a large proportion (over 99%, data not included) of spinal 18 
neuronal cultures were immunopositive for SC1 (with corresponding negative 19 
staining of isotype matched control wells) (Figs 2C-D). Uniform SC1 staining of 20 
spinal neuronal cultures was visible over large regions of interest, demonstrating 21 
that almost all spinal neurites visible under phase microscopy were SC1 22 
immunopositive (Fig 2E). Under high magnification the numerous cell bodies 23 
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which contribute to the formation of neuronal bodies were clearly visible. SC1 1 
staining appeared to uniform throughout the main neuronal cell cluster and along 2 
each individual neurite (2F). 3 
Embryonic chick spinal neuronal cultures are inhibited by neurocan and Nogo-A 4 
but not MAG 5 
Neuronal bodies with neurites were repelled by neurocan and Nogo-A in a 6 
concentration-dependent manner (Fig 3A and 3B). At high neurocan and Nogo-A 7 
concentrations (50μg/ml and 400g/ml respectively), neuronal adhesion and 8 
neurite outgrowth was almost completely inhibited (<1 neuronal cell aggregate 9 
with at least one neurite per image). At lower neurocan and Nogo-A 10 
concentrations (1-10μg/ml and 10-200μg/ml respectively), increasing numbers of 11 
neuronal bodies and neurites adhered to neurocan and Nogo-A substrates and 12 
extended neurites. In contrast, neuronal cultures seeded onto nitrocellulose: 13 
MAG substrate assays showed no preference for either substrate, i.e. neuronal 14 
bodies and neurites were not inhibited by MAG at any concentration (5-400g/ml) 15 
(Fig 3C). No evidence of neuronal cell death (as delineated by cell detachment or 16 
ethidium bromide nuclear localisation, data not included) was observed in any of 17 
the cultures tested. 18 
MSC promote embryonic chick spinal neuronal adhesion and neurite extension 19 
over substrata of neurocan, Nogo-A and MAG 20 
In MSC/ neuronal co-cultures, neuronal bodies were able to adhere and extend 21 
neurites over high neurocan and Nogo-A concentrations, such that ~5 neuronal 22 
bodies with neurites per image were present on 50μg/ml neurocan and ~3 23 
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neuronal bodies with neurites per image were present on 400g/ml Nogo-A. 1 
However, the inhibitory effects of neurocan and Nogo-A on neuronal adhesion 2 
and neurite outgrowth were only partially abrogated when compared to 3 
substrates of nitrocellulose. Some of the pre-seeded MSC appeared to align at 4 
the borders of nitrocellulose with neurocan or Nogo-A, suggesting that these cells 5 
were also inhibited by the nerve-inhibitory matrix molecules. However, it was 6 
apparent that even at high neurocan and Nogo-A concentrations, some MSC 7 
were still able to adhere to the neurocan and Nogo-A substrates and it was to 8 
these MSC that the adherent neuronal bodies and neurites were often co-9 
localised (Figs 4A and 4B). MSC, neuronal bodies and neurites were not inhibited 10 
by MAG at any concentration (5-400g/ml) (Fig 4C). Nonetheless, neuronal 11 
adhesion and neurite extension was increased on all substrates, including 12 
neurocan, Nogo-A, MAG and nitrocellulose when in co-culture with MSC in 13 
comparison to the absence of MSC. In addition, MSC traversing inhibitory 14 
substrata were immunopositive for the nerve permissive matrix molecules laminin 15 
and fibronectin (Fig 4D). 16 
MSC conditioned media (MSC-CM) promotes spinal neurite outgrowth over 17 
nitrocellulose but not neurocan or Nogo-A inhibitory substrata 18 
MSC-CM significantly increased spinal neurite extension over nitrocellulose 19 
substrates compared to control cultures in non-conditioned media (Fig 5A). We 20 
have detected several neurotrophic proteins in MSC-CM which may be important 21 
in stimulating spinal neurite outgrowth (Fig 5B). Of the neurotrophic factors 22 
identified, the levels of granulocyte colony stimulating factor (GCSF), fibroblast 23 
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growth factor-4 (FGF-4) and matrix metalloproteinase-8 (MMP-8) correlated 1 
significantly to the quantity of neurite outgrowth detected (Spearman Rank rs 2 
0.57, p=*0.014, rs 0.57, p=***<0.0001 and rs 0.66, p=**0.0032 respectively). 3 
However, MSC-CM alone was not sufficient stimulus to promote neurite 4 
outgrowth over inhibitory concentrations of neurocan or Nogo-A (Fig 5C).5 
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Discussion 1 
MSC transplantation for the treatment of SCI has proven efficacious in terms of 2 
promoting axonal regeneration and functional recovery in animal models and 3 
possibly in the clinic [10]. However, few definitive experiments have addressed 4 
the mechanisms involved in this process. We have developed a substrate choice 5 
assay to examine how spinal nerves interact in co-culture with MSC, specifically 6 
in the context of molecules that are present at the site of SCI and that are 7 
considered to form major inhibitors to axonal regeneration. Using this model we 8 
have shown that spinal neuronal bodies and neurites are inhibited by neurocan 9 
and Nogo-A in a concentration dependent manner, akin to DRG sensory 10 
neurites, which we have reported previously [30]. Increased concentrations of 11 
these extracellular inhibitors, however, were required to observe a similarly 12 
‘complete’ inhibition, e.g. 50g/ml of neurocan and 400g/ml Nogo-A completely 13 
inhibited spinal neurites, compared to 10g/ml of neural proteoglycans (which 14 
includes neurocan) and 200g/ml Nogo-A for the complete inhibition of DRG 15 
neurite outgrowth. However, unlike DRG sensory neurites, spinal cultures were 16 
not inhibited by MAG substrates at any of the concentrations tested (up to 17 
400g/ml). Hence, using this CNS system we have shown that one of the 18 
proposed inhibitors in the glial scar (MAG) may not be as potent in CNS systems 19 
as it is in DRG systems, which may have important implications for our 20 
understanding of nerve growth inhibition in the SCI setting. There is some 21 
supportive evidence in the literature for these findings which suggest that MAG 22 
may not be a crucial inhibitor of axonal regeneration in the CNS. For example, 23 
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Bartsch et al. [37] have shown that MAG deficient mice exhibit poor axonal 1 
regrowth following either optic nerve or corticospinal tract transection in vivo, 2 
although MAG has been shown by others to repel both peripheral nervous 3 
system (PNS) and CNS nerve growth [30, 38, 39]. 4 
 There are a number of distinctions between these neuronal cultures which 5 
might account for the differences we have observed in their response to 6 
substrate choice assays, compared to those results previously reported. The 7 
most obvious is the developmental stage of each tissue source; in the current 8 
study, spinal cultures were isolated 4.5 days after fertilization, compared to our 9 
previous work using DRG explants from day 10 embryos [30]. The expression of 10 
axonal guidance ligands and receptors, including myelin receptors are known to 11 
change throughout CNS and PNS development [40-44], which may explain why 12 
spinal and DRG cultures exhibit different sensitivities to MAG. In addition, both 13 
our current and previous methods of primary neuronal culture isolation included 14 
few (if any) purification steps and hence, these cultures are composed of mixed 15 
cell populations. We are in the process of characterising those ‘fibroblast-like’ 16 
cells visible in CNS and PNS cultures, which are likely to have influenced the 17 
sensitivity of neuronal cultures in substrate ‘choice’ assays. There is a possibility 18 
that other CNS cell types may have reduced the sensitivity of spinal neurites to 19 
MAG substrates, perhaps by physically masking or blocking inhibitory epitopes, 20 
or by secreting growth factors that blocked the inhibitory effects of MAG, e.g. 21 
brain derived neurotrophic factor (BDNF) [45]. In contrast, Schwann cells, which 22 
may be present in mixed PNS cultures, could exacerbate sensory nerve reactivity 23 
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to MAG via an additive effect, as Schwann cells themselves express nerve 1 
inhibitory MAG [46]. Furthermore, each culture environment varies greatly in 2 
media composition and growth factor supplementation which may also impact 3 
directly on the sensitivity of neurites to inhibitory substrates, including MAG [45, 4 
47]. For example, the exposure to neurotrophins has been shown to upregulate 5 
chimaerin (one of the Rho-GTPase activating proteins) in cerebellar neurons [48]. 6 
The expression of chimaerin in the cerebellum is correlated with abolishment of 7 
the inhibitory effects of MAG in development and ectopic expression of chimaerin 8 
in cerebellar neurons in vitro results in resistance to MAG induced neurite 9 
inhibition [48]. 10 
 We have demonstrated that MSC co-culture reduces the inhibitory effects 11 
of neurocan and Nogo-A on spinal neuronal adhesion and neurite outgrowth and 12 
enhances spinal neurite outgrowth over all of the substrates tested (neurocan, 13 
Nogo-A, MAG and nitrocellulose). We have also shown that MSC were repelled 14 
by high concentrations of neurocan and Nogo-A (but not MAG substrates). 15 
Hence, at high concentrations MSC could clearly be seen to align along inhibitory 16 
neurocan and Nogo-A borders. Although MSC were inhibited to a much lesser 17 
extent than spinal neuronal bodies and their associated neurites. This is not too 18 
surprising as we already know that MSC may have an increased capacity to 19 
adhere to and migrate over neural proteoglycans, Nogo-A and MAG compared to 20 
other cell types [30]. The exact mechanisms responsible for the abrogation of 21 
spinal nerve inhibition to neurocan and Nogo-A in MSC co-cultures may involve a 22 
number of complex paracrine, cell-matrix and cell contact-mediated interactions. 23 
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We and others have previously reported that MSC-CM promotes neurite 1 
outgrowth from DRG explants and that and that MSC synthesise a number of 2 
soluble cytokines and other growth factors that are known to stimulate nerve 3 
extension including NGF, BDNF and vascular endothelial growth factor [26, 30, 4 
49]. In this study we have shown that MSC-CM promotes spinal neurite 5 
outgrowth and contains several neurotrophic proteins, including GCSF, FGF-4 6 
and MMP-8 which significantly correlated to the level of spinal neurite stimulation 7 
observed. However, we show that MSC-CM alone was insufficient stimuli to 8 
promote spinal neurite extension over inhibitory concentrations of neurocan or 9 
Nogo-A. 10 
 There are other explanations which might account for spinal neurites 11 
extending over inhibitory substrates in MSC co-cultures. MSC are known to 12 
synthesise numerous extracellular matrices that support neuronal cells and 13 
provide an optimal surface for nerve growth [50]. We have shown using our 14 
model that migrating MSC provide permissive matrix ‘bridges’ of laminin and 15 
fibronectin over nerve inhibitory substrates. In addition, in many sequences and 16 
on all inhibitory substrata tested, MSC and spinal neurites co-localised. Whereby 17 
MSC appeared to act as adhesive ‘stepping stones’ for neurite extension. 18 
Alternatively, nerve-inhibitory molecules, particularly neural proteoglycans such 19 
as neurocan, may have been degraded by matrix metalloproteinases (MMPs), 20 
e.g. MMP-1, MMP-2, MMP-13, which MSC are known to synthesise [51]. We 21 
have previously demonstrated that cell contact-mediated events, such as towing 22 
of neurites and bridging of inhibitory substrata, may play an important role in 23 
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MSC abrogating the DRG nerve-inhibitory effects of neural proteoglycans, Nogo-1 
A and MAG [30]. Further experimentation using this system will aim to elucidate 2 
which of these mechanisms contribute to MSC stimulation of spinal neurite 3 
outgrowth over neurocan and Nogo-A, and to what extent. This may help to 4 
identify molecular targets to further enhance nerve growth in SCI environments. 5 
 There are few primary motor neuron culture protocols available for 6 
scientists to examine new therapies for CNS repair, particularly in the context of 7 
the injured spinal cord. We have modified an existing protocol [32] to test 8 
embryonic motor neurons, as characterised by SC1 staining, cultured on 9 
substrate choice assays. However, we acknowledge that our characterisation of 10 
spinal motor neuron cultures could be improved, e.g. by demonstrating a time 11 
course of viability and functionality (at least in theory), which we aim to 12 
investigate in future studies. None the less, we suggest that the development of 13 
this assay and its refinement for the testing of adult spinal motor neurite 14 
outgrowth over different growth surfaces will provide a valuable tool to examine 15 
motor neuron and glial cell-matrix and cell-cell interactions, not readily achieved 16 
when using complex in vivo models. We anticipate that this novel system may 17 
help to further elucidate some of the mechanisms of increased axonal 18 
regeneration that has been noted following MSC transplantation for the treatment 19 
of SCI, as well as having wider application in  the field of spinal therapeutics. 20 
21 
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Figure Legends 1 
Figure 1. Nitrocellulose promotes optimal growth of embryonic chick spinal 2 
neuronal cultures. A: Spinal cord cells formed many small fibroblastic aggregates 3 
with few neurites on plastic alone, larger cell aggregates with some neurites were 4 
formed on plastic pre-coated with laminin. Similar large cell aggregates were 5 
formed on nitrocellulose alone but with many more associated neurites. Cells 6 
seeded onto nitrocellulose pre-coated with laminin formed an almost confluent 7 
fibroblastic culture with few neurites. Examples of neurites are indicated by black 8 
arrows. Digitized images under phase contrast microscopy (calibration bar = 9 
100m). B: The number of cell aggregates with neurites was significantly 10 
increased on nitrocellulose substrates alone compared to plastic (with or without 11 
laminin) (*p=0.0042 and *p=0.0062 respectively, Mann Whitney U test: data 12 
shown are from at least 5 separate cultures and 5 separate images per culture 13 
combined ± SEM). No quantitation was attempted for nitrocellulose and laminin 14 
substrates, which supported few distinguishable cell aggregates or neurites 15 
amongst an almost confluent monolayer of fibroblastic cells. C: Most cell 16 
aggregates on plastic substrates were lost following fixation and immunostaining, 17 
some neurofilament staining of neuronal bodies and neurites was observed on 18 
plastic pre-coated with laminin. On nitrocellulose alone many neuronal bodies 19 
were immunopostive for neurofilament as were a complex network of associated 20 
neurites. The nuclei of cells seeded onto nitrocellulose pre-coated with laminin 21 
were stained but few neurites were visible. Digitized images under fluorescence 22 
microscopy (calibration bar = 100m). D: After immunostaining for neurofilament 23 
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the number of neuronal bodies with neurites was significantly increased on 1 
nitrocellulose substrates alone compared to plastic (with or without laminin) 2 
(*p=0.0034 and *p=0.0067 respectively, Mann Whitney U test: data shown are 3 
from at least 5 separate cultures and 5 separate images per culture combined ± 4 
SEM). Again, no quantitation was attempted for nitrocellulose and laminin 5 
substrates as few distinguishable cell aggregates, neuronal bodies or neurites 6 
were visible. 7 
Figure 2. Embryonic chick spinal neuronal cultures are immunopositive for SC1, 8 
a motor neuron marker. A-E: Representative digitized images of identical fields 9 
are shown from left to right. Left panels show phase images and right panels 10 
show immunolocalisation for SC1 (A and C) and isotype matched controls (B and 11 
D). A and B are DRG explants (negative for SC1 staining), C and D are spinal 12 
neuronal cultures (positive for SC1 staining). Calibration bars = 100m. E: At low 13 
magnification, encompassing a wide field of view, many if not all neuronal bodies 14 
and neurite networks in spinal neuronal cultures were immunopositive for SC1. 15 
Calibration bar = 500m. F: At high magnification, uniform SC1 immunopositivity 16 
was visible throughout the numerous cell bodies which cluster to form neuronal 17 
bodies but also along the length of each neurite emanating from them. 18 
Calibration bar = 100m. 19 
Figure 3. Neurocan, Nogo-A and MAG spinal neuronal adhesion and neurite 20 
outgrowth assays. A-C Digitized images of fluorescence microscopy show NF 21 
immunolabelled neuronal bodies and neurites (dotted lines illustrate the location 22 
of the neurocan, Nogo-A or MAG borders, calibration bars = 100m).  A: 23 
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Neurocan substrates repelled neuronal adhesion and neurite outgrowth in a dose 1 
dependant manner. The difference in the frequency of neuronal bodies with 2 
neurites which had adhered to neurocan substrates compared to nitrocellulose 3 
was significant at concentrations of 1, 5, 10 and 50g/ml (**p=0.059 and 4 
***p<0.0001 Mann Whitney U test). B: Nogo-A substrates repelled neuronal 5 
adhesion and neurite outgrowth in a dose dependant manner. The difference in 6 
the frequency of neuronal bodies with neurites which had adhered to Nogo-A 7 
substrates compared to nitrocellulose was significant at concentrations of 50, 8 
100, 200 and 400g/ml (***p<0.0001 Mann Whitney U test). C: There was no 9 
difference in the frequency of neuronal bodies with neurites which had adhered to 10 
MAG substrates compared to nitrocellulose at any of the concentrations tested 11 
(10, 50, 100, 200 or 400g/ml). Data shown are from at least 5 separate cultures 12 
and 5 separate images per culture combined +/-SEM.  13 
Figure 4. In MSC co-cultures, the inhibitory effects of neurocan and Nogo-A 14 
substrates on neuronal adhesion and neurite outgrowth were reduced. MSC co-15 
cultures also enhanced neuronal adhesion and neurite outgrowth over MAG. A-16 
C: Digitized images of identical fields are shown from left to right under 17 
fluorescence microscopy (left panels illustrate the location of the neurocan, 18 
Nogo-A or MAG and fluorescently labelled MSC, dotted lines illustrate the 19 
location of substrate borders, right panels show NF immunolabelled neuronal 20 
bodies and neurites, calibration bars = 100m).  A: MSC adhesion was reduced 21 
on high concentrations of neurocan (10 and 50g/ml) compared to nitrocellulose 22 
(*p=0.0217 and ***p<0.0001 Mann Whitney U test). Neuronal adhesion and 23 
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neurite extension was only inhibited at the highest concentration of neurocan 1 
(50g/ml) in MSC co-cultures (***p<0.0001 Mann Whitney U test). B: MSC 2 
adhesion was reduced on 400g/ml Nogo-A substrates compared to 3 
nitrocellulose (***p<0.0001 Mann Whitney U test). Neuronal adhesion and neurite 4 
extension was only inhibited at the highest concentration of Nogo-A (400g/ml) in 5 
MSC co-cultures (***p<0.0001 Mann Whitney U test). C: There was no difference 6 
in the frequency of MSC or neuronal bodies with neurites which had adhered to 7 
MAG substrates compared to nitrocellulose at any of the concentrations tested 8 
(10, 50, 100, 200 or 400g/ml). Black arrows indicate co-localisation of MSC and 9 
spinal neurites, white arrows indicate independent binding of neurites to inhibitory 10 
substrates. Data shown are from at least 5 separate cultures and 5 separate 11 
images per culture combined +/-SEM. D: Merged digitized phase and 12 
fluorescence images are shown (illustrating the location of MSC associated 13 
laminin or fibronectin, dotted lines illustrate the location of substrate borders, 14 
calibration bars = 100m).  MSC shown bridging nerve inhibitory substrata were 15 
immunopositive for laminin (right panel) and fibronectin.(middle panel). Left panel 16 
illustrates negative control staining for polyclonal antibodies.  17 
Figure 5. MSC conditioned media (MSC-CM) stimulates spinal neurite outgrowth, 18 
but not over inhibitory neurocan or Nogo-A substrata. A: Representative digitized 19 
images of neurite outgrowth over nitrocellulose in control media (top panel) and 20 
MSC-CM (bottom panel) under phase contrast microscopy are shown with 21 
digitized CellIQ® ‘neurite finder’ overlays, calibration bars = 100m. Analysing 22 
pooled data (n=6 MSC-CM) demonstrated a marked and significant increase in 23 
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neurite length following culture in MSC-CM compared to control medium 1 
(*p<0.0384 Mann Whitney U test). B: MSC-CM contained several neurotrophic 2 
proteins which were detected using custom designed antibody arrays. Arbitrary 3 
signal intensity readings were normalised to MSC number, data shown are from 4 
MSC-CM combined +/-SEM. C: MSC-CM was not sufficient stimiuli to promote 5 
neurite extension over inhibitory substrata of neurocan (top panel) or Nogo-A 6 
(bottom panel). Digitized images are shown under fluorescence microscopy show 7 
NF immunolabelled neuronal bodies and neurites (dotted lines illustrate the 8 
location of the neurocan or Nogo-A, calibration bars = 100m). There was no 9 
difference in the frequency of neuronal bodies with neurites which had adhered to 10 
nitrocellulose or inhibitory neurocan or Nogo-A substrata in neuronal growth 11 
media compared MSC-CM. Data shown are from at least 5 separate cultures and 12 
5 separate images per culture combined +/-SEM. 13 
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